Nicholas J. Silvestri, MD, FAAN

  • 2Articles
  • 18KReads
  • 2022Active
  • 2Collaborators
  • 2Citations

About

Nicholas J. Silvestri, MD, FAAN, is affiliated with the University at Buffalo Jacobs School of Medicine and Biomedical Sciences in New York. His publications focus on neurology, specifically exploring the role of antibodies and treatment strategies in myasthenia gravis. He has contributed to reviews on disease mechanisms and current as well as emerging therapies for generalized myasthenia gravis. His work has appeared in Psychiatrist.com in 2022.

Publications

PCC
Role of Antibodies in Myasthenia Gravis Treatment
Academic Highlights

Role of Antibodies in Myasthenia Gravis Treatment

October 27, 2022

Symptoms and disease pathophysiology of myasthenia gravis (MG) vary considerably with each patient, and their individual preferences and priorities add to the need for individualized treatment of this autoimmune...
, ,
PCC
Role of Antibodies in Myasthenia Gravis Treatment
Webcast

Role of Antibodies in Myasthenia Gravis Treatment

May 24, 2022

Patients with generalized myasthenia gravis (gMG) receive multiple immunosuppressive therapies, but with incomplete suppression of IgG autoantibodies. Review this update on gMG to learn about novel therapies that can...
, ,

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe